Viromed Medical AG ("Viromed"; ISIN: DE000A40ZVN7), a medical technology company specializing in cold plasma technology, has entered into a global distribution partnership with NEBU-TEC International med. Produkte Eike Kern GmbH ("NEBU-TEC"). The collaboration grants NEBU-TEC worldwide exclusive distribution rights for veterinary applications of PulmoPlas®, Viromed's cold plasma platform, combined with NEBU-TEC's nebulization technology. This partnership strengthens the international commercialization basis for innovative product solutions based on Viromed's cold plasma technology.
NEBU-TEC, an innovative and globally active medical technology company, develops, manufactures, and distributes state-of-the-art inhalation devices for human and veterinary medicine. With 30 years of experience in aerosol medicine, the company combines in-depth engineering expertise, its own device lines, and a comprehensive intellectual property portfolio to meet global healthcare needs. Under the partnership, Viromed's cold plasma technology will be integrated with NEBU-TEC's inhalation and nebulization solutions to open up new therapeutic applications for respiratory diseases.
The initial focus of the cooperation is the veterinary use of PulmoPlas® for pulmonary diseases in horses. This addresses a market with significant potential, particularly in the European equine market and equestrian sports, where there is high demand for effective and practical solutions for respiratory diseases. These conditions are widespread and affect a substantial proportion of the equine population. The market launch of PulmoPlas® vet is scheduled for later in 2026, and no approval is required in this area.
The devices used by NEBU-TEC are Class IIa medical devices under the EU Medical Device Regulation (MDR), which also allows for future use in humans in combination with PulmoPlas® med. Uwe Perbandt, CEO of Viromed Medical AG, stated: "The partnership with NEBU-TEC represents an important step in the international commercialization of our PulmoPlas® platform. Combining our cold plasma technology with NEBU-TEC's nebulization expertise opens up new fields of application in veterinary medicine and, going forward, also for applications in human medicine. We see attractive market potential here for this innovative approach."
Eike Kern, Managing Director of NEBU-TEC, emphasized: "The combination of inhalative application and cold plasma opens up new therapeutic possibilities. By bringing together complementary technologies, we are creating innovative and safe concepts for the treatment of both animals and humans – effective, safe and forward-looking." With this agreement, Viromed expands its strategic partnerships in cold plasma technology and lays the groundwork to position PulmoPlas® in additional international markets and applications. More information about Viromed can be found at www.viromed-medical-ag.de and about NEBU-TEC at www.nebu-tec.de.
